ZA200206917B - Pyridazinyl phenyl hydrazones useful against congestive heart failure. - Google Patents
Pyridazinyl phenyl hydrazones useful against congestive heart failure. Download PDFInfo
- Publication number
- ZA200206917B ZA200206917B ZA200206917A ZA200206917A ZA200206917B ZA 200206917 B ZA200206917 B ZA 200206917B ZA 200206917 A ZA200206917 A ZA 200206917A ZA 200206917 A ZA200206917 A ZA 200206917A ZA 200206917 B ZA200206917 B ZA 200206917B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydrogen
- methyl
- hydroxy
- compound
- alkyl
- Prior art date
Links
- -1 Pyridazinyl phenyl hydrazones Chemical class 0.000 title claims description 17
- 206010007559 Cardiac failure congestive Diseases 0.000 title claims description 6
- 206010019280 Heart failures Diseases 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 150000002429 hydrazines Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 238000007429 general method Methods 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000002585 Contractile Proteins Human genes 0.000 description 6
- 108010068426 Contractile Proteins Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 210000003540 papillary muscle Anatomy 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HDJKGUBFDGUPFK-SSDOTTSWSA-N (4r)-3-(4-hydrazinylphenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN)C=C1 HDJKGUBFDGUPFK-SSDOTTSWSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- RMJPDRUNCDRUQC-MCDZGGTQSA-M sodium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O RMJPDRUNCDRUQC-MCDZGGTQSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZGGBTNDTFFNWRD-LLVKDONJSA-N (4R)-3-[4-[2-[(4-hydroxy-3-methoxy-2-nitrophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound COC1=C(O)C=CC(C=NNC=2C=CC(=CC=2)C=2[C@@H](CC(=O)NN=2)C)=C1[N+]([O-])=O ZGGBTNDTFFNWRD-LLVKDONJSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NDDNYERKAPSDBT-UHFFFAOYSA-N 3-[4-[2-[(2-hydroxy-5-nitrophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC([N+]([O-])=O)=CC=C1O NDDNYERKAPSDBT-UHFFFAOYSA-N 0.000 description 1
- PHCNQUJHXJQLQR-UHFFFAOYSA-N 4-hydroxy-3-methoxy-2-nitrobenzaldehyde Chemical compound COC1=C(O)C=CC(C=O)=C1[N+]([O-])=O PHCNQUJHXJQLQR-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical class [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QPOLJQKSZXUNDS-UHFFFAOYSA-N 4-methyl-3-[4-[2-[(2,4,5-trihydroxyphenyl)methylidene]hydrazinyl]phenyl]-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1c1ccc(NN=Cc2cc(O)c(O)cc2O)cc1 QPOLJQKSZXUNDS-UHFFFAOYSA-N 0.000 description 1
- QAXDVKBGZRMSHF-UHFFFAOYSA-N 6-acetyl-5-hydroxy-4-methoxy-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(OC)=C(O)C2=C1CCN2C(C)=O QAXDVKBGZRMSHF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- GDMRFHZLKNYRRO-SSDOTTSWSA-N OR-1855 Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(N)C=C1 GDMRFHZLKNYRRO-SSDOTTSWSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000006277 halobenzyl group Chemical group 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 102000005681 phospholamban Human genes 0.000 description 1
- 108010059929 phospholamban Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000001424 substituent group Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20000577A FI20000577A0 (fi) | 2000-03-13 | 2000-03-13 | Pyridatsinyylifenyylihydratsoneja |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206917B true ZA200206917B (en) | 2003-07-30 |
Family
ID=8557913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206917A ZA200206917B (en) | 2000-03-13 | 2002-08-28 | Pyridazinyl phenyl hydrazones useful against congestive heart failure. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6699868B2 (no) |
| EP (1) | EP1265871B1 (no) |
| JP (1) | JP2003527375A (no) |
| KR (1) | KR20030001379A (no) |
| CN (1) | CN1191241C (no) |
| AR (1) | AR027644A1 (no) |
| AT (1) | ATE317388T1 (no) |
| AU (2) | AU4657701A (no) |
| BG (1) | BG65859B1 (no) |
| BR (1) | BR0109136A (no) |
| CA (1) | CA2403188A1 (no) |
| CZ (1) | CZ20022997A3 (no) |
| DE (1) | DE60117131T2 (no) |
| DK (1) | DK1265871T3 (no) |
| EA (1) | EA005574B1 (no) |
| EE (1) | EE200200520A (no) |
| ES (1) | ES2256222T3 (no) |
| FI (1) | FI20000577A0 (no) |
| HK (1) | HK1052008A1 (no) |
| HR (1) | HRP20020816A2 (no) |
| HU (1) | HUP0300177A3 (no) |
| IL (2) | IL151492A0 (no) |
| MX (1) | MXPA02008997A (no) |
| NO (1) | NO324172B1 (no) |
| NZ (1) | NZ521162A (no) |
| PL (1) | PL357107A1 (no) |
| RS (1) | RS50439B (no) |
| SI (1) | SI1265871T1 (no) |
| SK (1) | SK287163B6 (no) |
| UA (1) | UA74571C2 (no) |
| WO (1) | WO2001068611A1 (no) |
| ZA (1) | ZA200206917B (no) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0015228D0 (en) * | 2000-06-21 | 2000-08-16 | Portela & Ca Sa | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders |
| JP4561698B2 (ja) * | 2002-02-19 | 2010-10-13 | 小野薬品工業株式会社 | 縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| US20060276433A1 (en) * | 2003-03-31 | 2006-12-07 | Keiichi Kawagoe | Hydrazone derivative |
| GB0503962D0 (en) | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
| PL2069312T3 (pl) | 2006-07-25 | 2013-03-29 | Cephalon Inc | Pochodne pirydazynonu |
| CA2675176A1 (en) | 2007-01-17 | 2008-07-24 | Orion Corporation | Levosimendan for use in treating chronic valvular disease |
| KR20200024367A (ko) * | 2011-09-27 | 2020-03-06 | 제온 코포레이션 | 중합성 화합물의 제조 중간체 및 그 제조 방법 |
| TW201443023A (zh) * | 2013-01-18 | 2014-11-16 | 必治妥美雅史谷比公司 | 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮 |
| WO2019235569A1 (ja) * | 2018-06-08 | 2019-12-12 | 日産化学株式会社 | キナーゼ阻害剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3531658A1 (de) | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel |
| GB8903130D0 (en) * | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| US5185332A (en) * | 1989-02-11 | 1993-02-09 | Orion-Yhtyma Oy | Thiadiazines and pharmaceutical compositions thereof as well as method of use |
| FI973804A (fi) * | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
-
2000
- 2000-03-13 FI FI20000577A patent/FI20000577A0/fi unknown
-
2001
- 2001-03-12 KR KR1020027012066A patent/KR20030001379A/ko not_active Application Discontinuation
- 2001-03-12 CN CNB018065309A patent/CN1191241C/zh not_active Expired - Fee Related
- 2001-03-12 RS YUP-685/02A patent/RS50439B/sr unknown
- 2001-03-12 ES ES01919489T patent/ES2256222T3/es not_active Expired - Lifetime
- 2001-03-12 AU AU4657701A patent/AU4657701A/xx active Pending
- 2001-03-12 CZ CZ20022997A patent/CZ20022997A3/cs unknown
- 2001-03-12 CA CA002403188A patent/CA2403188A1/en not_active Abandoned
- 2001-03-12 AR ARP010101149A patent/AR027644A1/es unknown
- 2001-03-12 EA EA200200973A patent/EA005574B1/ru not_active IP Right Cessation
- 2001-03-12 JP JP2001567705A patent/JP2003527375A/ja not_active Withdrawn
- 2001-03-12 BR BR0109136-0A patent/BR0109136A/pt not_active IP Right Cessation
- 2001-03-12 EP EP01919489A patent/EP1265871B1/en not_active Expired - Lifetime
- 2001-03-12 US US10/221,348 patent/US6699868B2/en not_active Expired - Fee Related
- 2001-03-12 EE EEP200200520A patent/EE200200520A/xx unknown
- 2001-03-12 HU HU0300177A patent/HUP0300177A3/hu unknown
- 2001-03-12 AT AT01919489T patent/ATE317388T1/de not_active IP Right Cessation
- 2001-03-12 IL IL15149201A patent/IL151492A0/xx active IP Right Grant
- 2001-03-12 PL PL01357107A patent/PL357107A1/xx not_active Application Discontinuation
- 2001-03-12 SI SI200130518T patent/SI1265871T1/sl unknown
- 2001-03-12 DK DK01919489T patent/DK1265871T3/da active
- 2001-03-12 WO PCT/FI2001/000241 patent/WO2001068611A1/en active IP Right Grant
- 2001-03-12 NZ NZ521162A patent/NZ521162A/en unknown
- 2001-03-12 DE DE60117131T patent/DE60117131T2/de not_active Expired - Fee Related
- 2001-03-12 AU AU2001246577A patent/AU2001246577B2/en not_active Ceased
- 2001-03-12 MX MXPA02008997A patent/MXPA02008997A/es active IP Right Grant
- 2001-03-12 SK SK1288-2002A patent/SK287163B6/sk not_active IP Right Cessation
- 2001-12-03 UA UA2002108100A patent/UA74571C2/uk unknown
-
2002
- 2002-08-26 IL IL151492A patent/IL151492A/en not_active IP Right Cessation
- 2002-08-28 ZA ZA200206917A patent/ZA200206917B/en unknown
- 2002-09-05 NO NO20024247A patent/NO324172B1/no not_active IP Right Cessation
- 2002-10-08 BG BG107175A patent/BG65859B1/bg unknown
- 2002-10-11 HR HRP20020816 patent/HRP20020816A2/hr not_active Application Discontinuation
-
2003
- 2003-06-16 HK HK03104272A patent/HK1052008A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7960427B2 (en) | 5-hydroxyindole-3-carboxylate derivatives and uses thereof | |
| SK284295B6 (sk) | Derivát 4-(arylaminometylén)-2,4-dihydropyrazol-3-ónu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje | |
| ZA200206917B (en) | Pyridazinyl phenyl hydrazones useful against congestive heart failure. | |
| KR880001428B1 (ko) | 치환된 3-아미노-시드논-이민의 제조방법 | |
| JP2023511222A (ja) | 置換ピリダジノン類化合物とその用途 | |
| US4985453A (en) | Parabanic acid derivatives and pharmaceutical compositions thereof | |
| JPS6322565A (ja) | アルド−スレダクタ−ゼ抑制剤として有用なナフタレニルスルホニルイミダゾリジンジオンおよびそのチオキソ類似体 | |
| JP2716806B2 (ja) | ベンズイソオキサゾール誘導体を含有する脳機能改善剤 | |
| US5747495A (en) | Method for treating hypertension using pyrazolopyrimidine derivatives | |
| JP2004115508A (ja) | 熱傷皮膚組織の機能改善のための医薬 | |
| JP2023134657A (ja) | 新規抗腫瘍剤 | |
| JP2667511B2 (ja) | イソオキサゾール誘導体を含有する脳機能改善剤 | |
| JP2922930B2 (ja) | ヒダントイン誘導体及びその用途 | |
| JPWO2003067979A1 (ja) | 臓器移植時に用いる薬剤 | |
| JP2005343789A (ja) | 低酸素性虚血性脳障害予防・治療剤 | |
| KR880001429B1 (ko) | 치환된 3-아미노-시드논-이민의 제조방법 | |
| JP2004161720A (ja) | パラコート中毒の治療・予防剤 | |
| EP0146282A2 (en) | Pyrazinone compounds | |
| JPH03240785A (ja) | 新規なイソクマリン誘導体とその製法及び用途 | |
| JP2000515117A (ja) | 置換６―ｒ―１，３，４―チアジアジン―２―アミン、麻酔剤、心臓血管剤および代謝低下剤としてのそれらの使用、およびそれらを含有する医薬組成物 | |
| JPWO2003066051A1 (ja) | 心筋機能障害の予防及び／又は治療剤 | |
| JP2004002400A (ja) | 軽微低体温療法を行うために用いる脳保護及び／又は脳機能正常化のための医薬 | |
| JPH07224045A (ja) | ピリダジノン誘導体，その製法及びその用途 | |
| JP2003342173A (ja) | Ｎｏラジカル消去剤 |